# Autosomal dominant polycystic kidney disease (ADPKD)

## European advisory board meeting agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 08.00 – 8.20 | Welcome and introductions  
Dr David Wheeler, Chair |
| 08.20 – 8.30 | Otsuka Pharmaceuticals Europe Ltd (OPEL) background, aims and objectives  
Presenter Dr Andrew Makin |
| 08-30 – 10.30 | Session 1: A view from my clinic  
*Presentations of current patient demographics, pathways, diagnosis and management strategies by each delegate*  
*Facilitated by Dr David Wheeler* |
| 10.30 – 10.45 | Coffee break |
| 10.45 – 11.45 | Session 2: ADPKD patient identification and diagnosis  
*Open discussion on the Session 1 delegate presentations facilitated by Dr David Wheeler* |
| 11.45 – 13.00 | Session 3: Current ADPKD management  
*Open discussion on the Session 1 delegate presentations facilitated by Dr David Wheeler* |
| 13.00–13.45 | Lunch |
*Workshop discussion facilitated by Dr David Wheeler, based on discussions in Session 1 and 2* |
| 14.45 – 15.00 | Coffee break |
| 15.00 – 16.00 | Session 5: Current ADPKD Management – developing a framework of minimum standards and best practice  
*Workshop discussion facilitated by Dr David Wheeler, based on discussions in Session 1 and 3* |
| 16.00 -16.30 | Summary of meeting and next steps  
*Joint summary from Dr David Wheeler and Dr Andrew Makin* |
| 16.30 | Meeting close |